Lei Hua

Lei Hua

Auto-generated profile, based on publicly available information

Lei Hua

Department of Pain, Wuhan Fourth Hospital, Wuhan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Investigación Clínica
Verified
Journal Article
Open access
LHLei Hua
Lei Hua
WZWaiping Zhou
Waiping Zhou
MLMengjie Li
Mengjie Li
RLRongchun Li
Rongchun Li
To elucidate the effects of phillygenin (PHI) and the potential mechanism on TLR4 and MyD88/NF-κB signalling in neuropathic pain in an-imal studies, chronic constriction injury (CCI) models were constructed for neuropathic pain induction using male Sprague-Dawley rats. PHI (20 mg/kg) was delivered through intragastric administration. Von Frey and Hargreaves tests were implemented to determine the 50% paw-withdrawal threshold (PWT) and paw-withdrawal latency (PWL). A nitric oxide (NO) assay was used for NO level detection, and an ELISA assay was employed to measure the expression of proinflammatory cytokines. Western blotting and RT-qPCR were conducted for protein and mRNA level detection. Treatment with PHI significantly enhanced 50% of PWT and PWL. PHI significantly decreased the levels of NO and reduced the levels of TNF-α, IL -1β, and IL -6. PHI also downregulated TLR4 and MyD88 expressions and inhibited the phosphorylation of NF-κB.PHI ameliorated in-flammatory status and alleviated neuropathic pain in CCI rats, targeting TLR4 and suppressing MyD88/NF-κB signalling.